• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胶质母细胞瘤:在世界卫生组织 CNS5 分类中的变化概念。

Glioblastoma: Changing concepts in the WHO CNS5 classification.

机构信息

Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, USA.

Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri, USA.

出版信息

Indian J Pathol Microbiol. 2022 May;65(Supplement):S24-S32. doi: 10.4103/ijpm.ijpm_1109_21.

DOI:10.4103/ijpm.ijpm_1109_21
PMID:35562131
Abstract

Glioblastoma is the most common malignant central nervous system (CNS) tumor in adults. Acute common clinical symptoms include headache, seizure, behavior changes, focal neurological deficits, and signs of increased intracranial pressure. The classic MRI finding of glioblastoma is an irregularly shaped, rim-enhancing or ring-enhancing lesion with a central dark area of necrosis. This constellation of features correlates with microscopic findings of tumor necrosis and microvascular proliferation. Besides these common features, several well-recognized histological subtypes include giant cell glioblastoma, granular cell glioblastoma, gliosarcoma, glioblastoma with a primitive neuronal component, small cell glioblastoma, and epithelioid glioblastoma. While glioblastoma was historically classified as isocitrate dehydrogenase (IDH)-wildtype and IDH-mutant groups, the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) and the fifth edition of the WHO Classification of Tumors of the Central Nervous System clearly updated the nomenclature to reflect glioblastoma to be compatible with wildtype IDH status only. Therefore, glioblastoma is now defined as "a diffuse, astrocytic glioma that is IDH-wildtype and H3-wildtype and has one or more of the following histological or genetic features: microvascular proliferation, necrosis, Telomerase reverse transcriptase promoter mutation, Epidermal growth factor receptor gene amplification, +7/-10 chromosome copy-number changes (CNS WHO grade 4)."

摘要

胶质母细胞瘤是成人中最常见的恶性中枢神经系统 (CNS) 肿瘤。急性常见的临床症状包括头痛、癫痫、行为改变、局灶性神经功能缺损和颅内压升高的迹象。胶质母细胞瘤的典型 MRI 表现为形状不规则、边缘增强或环形增强病变,伴有中央坏死的暗区。这种特征组合与肿瘤坏死和微血管增殖的显微镜发现相关。除了这些常见特征外,还有几种公认的组织学亚型,包括巨细胞胶质母细胞瘤、颗粒细胞胶质母细胞瘤、胶质肉瘤、具有原始神经元成分的胶质母细胞瘤、小细胞胶质母细胞瘤和上皮样胶质母细胞瘤。虽然胶质母细胞瘤历史上被分类为异柠檬酸脱氢酶(IDH)-野生型和 IDH-突变型,但中枢神经系统肿瘤分类的信息分子和实用方法联盟(cIMPACT-NOW)和第五版世界卫生组织中枢神经系统肿瘤分类明确更新了命名法,以反映胶质母细胞瘤仅与野生型 IDH 状态兼容。因此,胶质母细胞瘤现在被定义为“弥漫性星形细胞瘤,IDH 野生型和 H3 野生型,具有以下一种或多种组织学或遗传特征:微血管增殖、坏死、端粒酶逆转录酶启动子突变、表皮生长因子受体基因扩增、+7/-10 染色体拷贝数变化(CNS WHO 分级 4)”。

相似文献

1
Glioblastoma: Changing concepts in the WHO CNS5 classification.胶质母细胞瘤:在世界卫生组织 CNS5 分类中的变化概念。
Indian J Pathol Microbiol. 2022 May;65(Supplement):S24-S32. doi: 10.4103/ijpm.ijpm_1109_21.
2
Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?超越 2016 年世界卫生组织中枢神经系统肿瘤分类:从临床医生的角度看,胶质瘤有哪些新进展?
Curr Opin Neurol. 2020 Dec;33(6):701-706. doi: 10.1097/WCO.0000000000000871.
3
Major Changes in 2021 World Health Organization Classification of Central Nervous System Tumors.2021 年世界卫生组织中枢神经系统肿瘤分类的重大变化。
Radiographics. 2022 Sep-Oct;42(5):1474-1493. doi: 10.1148/rg.210236. Epub 2022 Jul 8.
4
[World Health Organization Classification of Central Nervous System Tumours, 5 Edition:Points of the Update and the Current Status].[《世界卫生组织中枢神经系统肿瘤分类》第5版:更新要点与现状]
No Shinkei Geka. 2023 Mar;51(2):349-363. doi: 10.11477/mf.1436204751.
5
Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.弥漫性星形细胞瘤,IDH1/2 野生型,具有胶质母细胞瘤的分子特征,WHO 分级 IV:对 cIMPACT-NOW 标准的确认。
Neuro Oncol. 2020 Apr 15;22(4):515-523. doi: 10.1093/neuonc/noz200.
6
cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".cIMPACT-NOW更新3:“弥漫性星形细胞胶质瘤,IDH野生型,具有胶质母细胞瘤分子特征,WHO四级”的推荐诊断标准。
Acta Neuropathol. 2018 Nov;136(5):805-810. doi: 10.1007/s00401-018-1913-0. Epub 2018 Sep 26.
7
TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.端粒酶逆转录酶(TERT)启动子突变状态对于诊断具有胶质母细胞瘤分子特征的异柠檬酸脱氢酶(IDH)野生型弥漫性星形细胞胶质瘤而言是必要且充分的。
Acta Neuropathol. 2021 Aug;142(2):323-338. doi: 10.1007/s00401-021-02337-9. Epub 2021 Jun 20.
8
A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted.成人弥漫性神经胶质瘤 WHO CNS5 分类的综述,特别论及星形细胞瘤、IDH 突变型和少突胶质细胞瘤、IDH 突变型和 1p/19q 联合缺失型。
Indian J Pathol Microbiol. 2022 May;65(Supplement):S14-S23. doi: 10.4103/ijpm.ijpm_34_22.
9
Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.成人脑胶质瘤的靶向下一代测序用于回顾性预后评估和前瞻性诊断。
Neuropathol Appl Neurobiol. 2021 Feb;47(1):108-126. doi: 10.1111/nan.12645. Epub 2020 Aug 17.
10
Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes.前瞻性基于基因组的“早期/进展期”和“采样不足”IDH 野生型胶质母细胞瘤的识别可改善临床结局。
Neuro Oncol. 2022 Oct 3;24(10):1749-1762. doi: 10.1093/neuonc/noac089.

引用本文的文献

1
Nanotechnology in brain cancer treatment: The role of gold nanoparticles as therapeutic enhancers.纳米技术在脑癌治疗中的应用:金纳米颗粒作为治疗增强剂的作用。
Ibrain. 2025 May 10;11(2):119-145. doi: 10.1002/ibra.12198. eCollection 2025 Summer.
2
A novel cuproptosis-associated LncRNA model predicting prognostic and immunotherapy response for glioma.一种预测胶质瘤预后和免疫治疗反应的新型铜死亡相关长链非编码RNA模型。
Discov Oncol. 2025 Jun 13;16(1):1089. doi: 10.1007/s12672-025-02912-6.
3
Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes.
胶质母细胞瘤:临床表现、多学科管理及长期预后
Cancers (Basel). 2025 Jan 5;17(1):146. doi: 10.3390/cancers17010146.
4
Revolutionizing Glioblastoma Treatment: A Comprehensive Overview of Modern Therapeutic Approaches.革命性的脑胶质瘤治疗方法:现代治疗方法的全面概述。
Int J Mol Sci. 2024 May 26;25(11):5774. doi: 10.3390/ijms25115774.
5
A radiomics-based nomogram may be useful for predicting telomerase reverse transcriptase promoter mutation status in adult glioblastoma.基于放射组学的列线图可能有助于预测成人胶质母细胞瘤中端粒酶逆转录酶启动子突变状态。
Brain Behav. 2024 May;14(5):e3528. doi: 10.1002/brb3.3528.
6
Development and validation of an immunogenic cell death-related prognostic model, and landscape of the tumor immune microenvironment in glioblastoma.胶质母细胞瘤中免疫原性细胞死亡相关预后模型的建立与验证以及肿瘤免疫微环境全景分析
Genes Dis. 2023 Jun 28;11(3):101001. doi: 10.1016/j.gendis.2023.04.032. eCollection 2024 May.
7
Biomolecules to Biomarkers? U87MG Marker Evaluation on the Path towards Glioblastoma Multiforme Pathogenesis.生物分子能成为生物标志物吗?U87MG标志物在多形性胶质母细胞瘤发病机制研究中的评估
Pharmaceutics. 2024 Jan 18;16(1):123. doi: 10.3390/pharmaceutics16010123.
8
NeuroD4 converts glioblastoma cells into neuron-like cells through the SLC7A11-GSH-GPX4 antioxidant axis.NeuroD4通过SLC7A11-谷胱甘肽-谷胱甘肽过氧化物酶4抗氧化轴将胶质母细胞瘤细胞转化为神经元样细胞。
Cell Death Discov. 2023 Aug 15;9(1):297. doi: 10.1038/s41420-023-01595-8.
9
Quantifying the Growth of Glioblastoma Tumors Using Multimodal MRI Brain Images.使用多模态MRI脑图像量化胶质母细胞瘤肿瘤的生长
Cancers (Basel). 2023 Jul 14;15(14):3614. doi: 10.3390/cancers15143614.
10
Insights into the Role of LncRNAs and miRNAs in Glioma Progression and Their Potential as Novel Therapeutic Targets.长链非编码RNA和微小RNA在胶质瘤进展中的作用及其作为新型治疗靶点的潜力的见解
Cancers (Basel). 2023 Jun 22;15(13):3298. doi: 10.3390/cancers15133298.